HCW starts Actinium Pharma at buy

H.C. Wainwright has launched coverage of Actinium Pharmaceuticals (NASDAQ:ATNM) with a “buy” rating and a price target of $8. The stock closed at $1.98 on Friday.

“We believe that due to a long history of pivotal failures on top of a scarcity of treatment options, AML is likely to start enjoying some regulatory slack over the next few years, with Actinium well-positioned for value with two pedigreed assets tackling two different stages of the disease,” writes analyst Andrew Fein.

These include Actimab-A (anti-CD33 antibody conjugated to the isotope Actinium-225, based on work from the Memorial Sloan Kettering Cancer Center) as front-line therapy in elderly AML patients; and Iomab-B (anti-CD45 antibody conjugated to the isotope Iodine-131, based on work from the Fred Hutchinson Cancer Center) as conditioning therapy for bone marrow transplant in relapsed/refractory elderly AML patients.

“We believe that the relative stages of the assets contribute positively to the value proposition and risk consideration,” he added.

Lomab-B, which in Mr. Fein’s view is the lower-risk asset targeting a smaller market, is entering a BLA-supporting Phase 3 study in the first half of 2016, while Actimab-A, which he views is the higher-risk asset targeting a more lucrative market, is currently in Phase 1/2, with an option to advance directly to Phase 3 subsequently.

He said that while AML has currently attracted a spectrum of heavy-hitting developers, including Seattle Genetics and Abbvie, “we believe that Actinium’s two clinical programs under a $87-million market capitalization offer a cheap long opportunity for investors interested in AML therapeutics.”

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.